Table 2 Characteristics of CNS metastasis
From: Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasis
Characteristic | Freq. (%) |
|---|---|
Time-point of CNS metastasis | |
Platinum sensitive | 14 (53.8) |
Platinum resistant | 11 (42.3) |
Unknown | 1 (3.8) |
Previous CT lines before diagnosis CNS metastasis | |
1 | 12 (46.2) |
2 | 2 (7.7) |
3 | 3 (11.5) |
4 | 5 (19.2) |
5 | 3 (11.5) |
Unknown | 1 (3.8) |
BM as only site of metastatic disease | |
Yes | 6 (23.2) |
No | 20 (76.9) |
Extra-CNS disease progression | |
Yes | 11 (42.6) |
No | 14 (53.8) |
Unknown | 1 (3.8) |
Number of metastasis (median /IQR) | 4.5 (1–20) |
Metastasis size (median/IQR) | 3.2 (2.1–3.7) |
Platinum free interval (median/IQR) | 10.9 (4.2–22.4) |
Time from diagnosis (median/IQR) | 31.8 (18.9–55.8) |
Treatment | |
Surgery + WBRT or SRT | 8 (30.8) |
WBRT | 15 (57.7) |
SRT | 5 (19.2) |
Chemotheraphy | 4 (15.4) |